Cue Biopharma, Inc. (CUE)

Cue Biopharma Statistics

Total Valuation

Cue Biopharma has a market cap or net worth of $63.98 million. The enterprise value is $41.08 million.

Market Cap	63.98M
Enterprise Value	41.08M

Important Dates

The last earnings date was Thursday, November 14, 2024, after market close.

Earnings Date	Nov 14, 2024
Ex-Dividend Date	n/a

Share Statistics

Cue Biopharma has 63.35 million shares outstanding. The number of shares has increased by 13.18% in one year.

Current Share Class	63.35M
Shares Outstanding	63.35M
Shares Change (YoY)	+13.18%
Shares Change (QoQ)	+2.10%
Owned by Insiders (%)	0.83%
Owned by Institutions (%)	25.20%
Float	62.83M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	5.25
Forward PS	10.42
PB Ratio	2.40
P/TBV Ratio	2.52
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	4.31
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.22, with a Debt / Equity ratio of 0.37.

Current Ratio	2.22
Quick Ratio	2.12
Debt / Equity	0.37
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-39.69

Financial Efficiency

Return on equity (ROE) is -131.15% and return on invested capital (ROIC) is -60.74%.

Return on Equity (ROE)	-131.15%
Return on Assets (ROA)	-50.18%
Return on Capital (ROIC)	-60.74%
Revenue Per Employee	$179,849
Profits Per Employee	-$841,736
Employee Count	53
Asset Turnover	0.17
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -65.53% in the last 52 weeks. The beta is 1.63, so Cue Biopharma's price volatility has been higher than the market average.

Beta (5Y)	1.63
52-Week Price Change	-65.53%
50-Day Moving Average	1.31
200-Day Moving Average	1.27
Relative Strength Index (RSI)	41.72
Average Volume (20 Days)	354,895

Short Selling Information

The latest short interest is 1.00 million, so 1.59% of the outstanding shares have been sold short.

Short Interest	1.00M
Short Previous Month	1.07M
Short % of Shares Out	1.59%
Short % of Float	1.60%
Short Ratio (days to cover)	1.54

Income Statement

In the last 12 months, Cue Biopharma had revenue of $9.53 million and -$44.61 million in losses. Loss per share was -$0.90.

Revenue	9.53M
Gross Profit	-27.76M
Operating Income	-45.64M
Pretax Income	-49.97M
Net Income	-44.61M
EBITDA	-45.23M
EBIT	-45.64M
Loss Per Share	-$0.90

Balance Sheet

The company has $32.42 million in cash and $9.51 million in debt, giving a net cash position of $22.91 million or $0.36 per share.

Cash & Cash Equivalents	32.42M
Total Debt	9.51M
Net Cash	22.91M
Net Cash Per Share	$0.36
Equity (Book Value)	25.37M
Book Value Per Share	0.42
Working Capital	20.47M

Cash Flow

In the last 12 months, operating cash flow was -$38.26 million and capital expenditures -$64,000, giving a free cash flow of -$38.32 million.

Operating Cash Flow	-38.26M
Capital Expenditures	-64,000
Free Cash Flow	-38.32M
FCF Per Share	-$0.60

Margins

Gross Margin	-291.24%
Operating Margin	-478.80%
Pretax Margin	-468.02%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Cue Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-13.18%
Shareholder Yield	-13.18%
Earnings Yield	-69.72%
FCF Yield	-59.89%

Analyst Forecast

The average price target for Cue Biopharma is $5.00, which is 395.05% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$5.00
Price Target Difference	395.05%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	23.56%
EPS Growth Forecast (5Y)	-12.58%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Cue Biopharma has an Altman Z-Score of -10.46 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-10.46
Piotroski F-Score	4